Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors Trial (BENEFIT‐EXT) study compared more or less intensive belatacept‐based immunosuppression with cyclosporine (CsA)–based immunosuppression in recipients of extended criteria donor kidneys. In this post hoc analysis, patient outcomes were assessed according to donor kidney subtype. In total, 68.9% of patients received an expanded criteria donor kidney (United Network for Organ Sharing definition), 10.1% received a donation after cardiac death kidney, and 21.0% received a kidney with an anticipated cold ischemic time ≥24 h. Over 7 years, time to death or graft loss was similar between belatacept‐ and CsA‐based immunosuppression, regardless of donor kidney subtype. In all three donor kidney cohorts, estimated mean GFR increased over months 1–84 for belatacept‐based treatment but declined for CsA‐based treatment. The estimated differences in GFR significantly favored each belatacept‐based regimen versus the CsA‐based regimen in the three subgroups (p < 0.0001 for overall treatment effect). No differences in the safety profile of belatacept were observed by donor kidney subtype.

• Publication year

  2016

• Venue

  American Journal of Transplantation

• Publication date

  2016-07-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ajt.13886PMID 27232116PMCID 5215636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Belatacept and Long-Term Outcomes in Kidney Transplantation.

  2016influential reference
• Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

  2016influential reference
• Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

  2016cited by this paper
• Expanded criteria donor and donation after circulatory death renal allografts in the West of Scotland: Their place in the kidney allocation process.

  2016cited by this paper
• OPTN/SRTR 2012 Annual Data Report: Kidney

  2014cited by this paper
• Belatacept for kidney transplant recipients.

  2014cited by this paper
• Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

  2012cited by this paper
• Three‐Year Outcomes from BENEFIT, a Randomized, Active‐Controlled, Parallel‐Group Study in Adult Kidney Transplant Recipients

  2012cited by this paper
• Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk.

  2012cited by this paper
• Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on post‐transplant outcomes

  2011cited by this paper
• The relationship between kidney function and long-term graft survival after kidney transplant.

  2011cited by this paper
• Opportunities and challenges of expanded criteria organs in liver and kidney transplantation as a response to organ shortage.

  2011cited by this paper
• Optimal immunosuppression to prevent chronic allograft dysfunction.

  2010cited by this paper
• A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

  2010influential reference
• Kidneys from donors after cardiac death provide survival benefit.

  2010cited by this paper
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

  2010cited by this paper
• Older donors and older recipients in kidney transplantation.

  2010cited by this paper
• Rapid decline of kidney function increases cardiovascular risk in the elderly.

  2009cited by this paper
• Outcomes of Transplantation Using Kidneys From Donors Meeting Expanded Criteria in Australia and New Zealand, 1991 to 2005

  2009cited by this paper
• MDRD-Estimated GFR at One Year Post-Renal Transplant Is a Predictor of Long-Term Graft Function

  2008cited by this paper
• Outcomes of Kidneys from Donors After Cardiac Death: Implications for Allocation and Preservation

  2007cited by this paper
• Outcome of Kidney Transplantation Using Expanded Criteria Donors and Donation After Cardiac Death Kidneys: Realities and Costs

  2007cited by this paper
• Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant

  2006cited by this paper
• Expanded criteria donors for kidney transplantation.

  2005cited by this paper
• The natural history of chronic allograft nephropathy.

  2005cited by this paper
• Expanding the donor pool to increase renal transplantation.

  2005cited by this paper
• Current status of kidney and pancreas transplantation in the United States, 1994–2003

  2005cited by this paper
• Renal Dysfunction as a Risk Factor for Mortality and Cardiovascular Disease in Renal Transplantation: Experience from the Assessment of Lescol in Renal Transplantation Trial

  2005cited by this paper
• Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression

  2005cited by this paper
• Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties

  2005cited by this paper
• Quality of life of patients having renal replacement therapy.

  2005cited by this paper
• Historical keywords: trial.

  2004cited by this paper
• Expanded criteria donors for kidney transplantation

  2003cited by this paper
• Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2

  2003cited by this paper
• The natural history of chronic allograft nephropathy.

  2003cited by this paper
• Post-transplant renal function in the first year predicts long-term kidney transplant survival.

  2002cited by this paper
• Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates.

  2001cited by this paper
• COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT

  2000cited by this paper
• Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

  1999cited by this paper

• Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.

  2026cites this paper
• Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches.

  2026cites this paper
• Tailoring of Immunosuppression With Belatacept in De Novo and Conversion Settings and Risk Mitigation Strategies.

  2025cites this paper
• New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review

  2024cites this paper
• Use of a Belatacept-based Immunosuppression for Kidney Transplantation From Donors After Circulatory Death: A Paired Kidney Analysis

  2024cites this paper
• Utility of a fusion protein T‐cell co‐stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center

  2024cites this paper
• Porcine anti-human lymphocyte immunoglobulin depletes the lymphocyte population to promote successful kidney transplantation

  2023cites this paper
• Antibacterial and antioxidant chitosan nanoparticles improve the preservation effect for donor kidneys in vitro.

  2022cites this paper
• Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

  2022cites this paper
• Kidney transplant outcome of expanded criteria donors after circulatory death.

  2022cites this paper
• An Assessment of Ineligible Donor Use in Solid Organ Transplant

  2022cites this paper
• Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial

  2022cites this paper
• Impaired renal function before kidney procurement has a deleterious impact on allograft survival in very old deceased kidney donors

  2021cites this paper
• Kidney transplant outcome of expanded criteria donors after circulatory death.

  2021cites this paper
• Analysis of the acceptance practice of deceased donor kidneys in a single Hungarian transplant centre

  2021cites this paper
• Therapeutic use of human tissues and organs for transplants: adverse events and biosurveillance actions

  2021cites this paper
• A kadáverdonor-vesék elfogadási gyakorlatának vizsgálata a debreceni transzplantációs centrumban the acceptance practice of deceased donor kidneys in a single Hungarian transplant centre

  2021cites this paper
• Penggunaan Produk Biosimilar pada Transplantasi Ginjal

  2021cites this paper
• Tratamiento de COVID-19 en receptores de trasplante renal

  2020cites this paper
• The Relationship between Timing of Pretransplant Kidney Biopsy, Graft Loss, and Survival in Kidney Transplantation: An Italian Cohort Study

  2020cites this paper
• Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins

  2020cites this paper
• Advances in Immunosuppression

  2020cites this paper
• Mechanisms and clinical applications of immunosuppressive medications

  2020cites this paper
• Outcomes and implications of a single brain death examination policy on organ donation outcomes at a high-volume trauma center

  2020cites this paper
• [Very-old deceased donors in kidney transplantation: How far can we go?]

  2020cites this paper
• Le tissu adipeux péri-rénal : modèle d'étude de la vasculo-compétence du transplant rénal prélevé chez le donneur âgé à haut risque cardiovasculaire

  2019cites this paper
• Belatacept in kidney transplantation and its limitations

  2019cites this paper
• Immunosuppression

  2019cites this paper
• Belatacept‐based immunosuppression: A calcineurin inhibitor‐sparing regimen in heart transplant recipients

  2019cites this paper
• Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience

  2019cites this paper
• Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs

  2018cites this paper
• [Focusing on kidney transplantation in the elderly].

  2018cites this paper
• Fc‐Silent Anti‐CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection

  2017cites this paper
• Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions.

  2017cites this paper
• Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice

  2017cites this paper
• Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients

  2017cites this paper
• Transplantation rénale et sujet âgé : mise au point

  2017cites this paper
• Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

  2016cites this paper